Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
This study has been completed.
Sponsor:
Biogen Idec
Collaborator:
Elan Pharmaceuticals
Information provided by:
Biogen Idec
ClinicalTrials.gov Identifier:
NCT00027300
First received: November 30, 2001
Last updated: June 15, 2009
Last verified: June 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | January 2005 |
| Primary Completion Date: | November 2004 (Final data collection date for primary outcome measure) |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):